The main objective of the drug delivery method, pulmonary drug delivery, is to place inhaled pharmacological agents in the lower airways using tools that facilitate oral inhalation of drug formulations. They are widely used in various end-user industries, including healthcare facilities like hospitals, clinics, and nursing homes. Various equipment is used for respiratory delivery, such as nebulizers, metered-dose inhalers, and dry powder inhalers. The lungs are used to deliver inhaled beta-agonists, corticosteroids, and anticholinergic drugs to treat asthma and chronic obstructive pulmonary disease (COPD). The pulmonary administration method offers several benefits. The medication is applied directly to the disease site to treat respiratory infections.
According to Data Bridge Market Research, Pulmonary Drug Delivery Market is valued at USD 47.85 billion in 2022, will reach USD 72.88 billion by 2030, growing at a CAGR of 5.4% during the forecast period of 2023 to 2030..
"Increasing prevalence of respiratory diseases surge market demand"
The increasing prevalence of respiratory diseases, including asthma, COPD, and cystic fibrosis, is a significant driver for the pulmonary drug delivery market. These conditions require effective treatments directly targeting the lungs to provide quick relief or long-term management. Pulmonary drug delivery offers a direct and efficient method of delivering medications to the respiratory system, meeting the demand for optimized therapies and contributing to market growth.
What restraints the growth of the pulmonary drug delivery market?
"Limited drug compatibility can impede the market growth”
The limited drug compatibility is a restraint in the pulmonary drug delivery market, as not all drugs can be effectively delivered via inhalation. Factors like stability, solubility, and suitability for inhalation impact drug formulation for pulmonary delivery. This limitation narrows down the range of drugs that can be administered through pulmonary routes, limiting market potential. Overcoming these challenges requires innovative formulation technologies and careful consideration of drug properties for successful pulmonary delivery.
Segmentation: Global Pulmonary Drug Delivery Market
The pulmonary drug delivery market is segmented on the basis of formulations, canister type, application, and end-user.
- On the basis of formulations, the pulmonary drug delivery market is segmented into type, device type, accessories.
- On the basis of canister type, the pulmonary drug delivery market is segmented into plain canister, coated canister.
- On the basis of application, the pulmonary drug delivery market is segmented into chronic obstructive pulmonary disease (copd), asthma, cystic fibrosis, allergic rhinitis, other
- On the basis of end-user, the pulmonary drug delivery market is segmented into hospitals and clinics, home care settings.
Regional Insights: North America Dominates the Global Pulmonary Drug Delivery Market
North America dominates the market due to the growing prevalence of respiratory and lung disorders, technological advancement, and increasing awareness. Furthermore, through an increase in the majority of pulmonary diseases, the presence of significant players in the development and production of medications for pulmonary diseases, an increase in the number of hospitals and diagnostic centers, and local government initiatives for the treatment of pulmonary diseases.
Asia-Pacific is expected to show a rapid and lucrative growth rate in the forecast period owing to Japan's growing elderly population and rising disposable income. Additionally, the regional market will benefit from an increase in the number of respiratory patients, the acceptance of pulmonary drug delivery systems, and growing government efforts to upgrade the region's healthcare infrastructure.
To know more about the study, visit, https://www.databridgemarketresearch.com/es/reports/global-pulmonary-drug-delivery-market
Recent Developments in Global Pulmonary Drug Delivery Market
- In 2022, With the acquisition of Subintro by RIGImmune, it now has access to state-of-the-art topical delivery systems. With the help of this agreement, the biotech will be in a better position to develop innovative RNA therapies and vaccine adjuvants for local mucosal delivery.
- In 2022, Aptar Pharma purchased the global license for the orbital dry powder inhaler (DPI). With this acquisition, Aptar Pharma will be able to meet the growing demand for high-dose lung treatment administration that is safe and simple.
- In 2020, A New Drug Application (NDA) for UPTRAVI (selexipag) as an intravenous (IV) injection to treat pulmonary arterial hypertension was submitted to the U.S. Food and Drug Administration (FDA) by Johnson & Johnson's Janssen Pharmaceutical Companies.
- In 2020, According to information provided by Novartis Pharma K.K. ("Novartis Pharma"), the Japanese Ministry of Health, Labour, and Welfare (MHLW) simultaneously approved new treatment options for Japanese patients. TabrectaTM (capmatinib, formerly INC280) is an oral MET inhibitor for advanced and recurrent untreatable non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METex14) mutation.
The Prominent Key Players Operating in the Global Pulmonary Drug Delivery Market Include:
- F. Hoffmann-La Roche Ltd (Switzerland)
- MannKind Corporation (U.S.)
- OMRON Healthcare, Inc. (Japan)
- Mylan N.V (U.S.)
- 3M (U.S.)
- Koninklijke Philips N.V. (Netherlands)
- Merck & Co., Inc., (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sunovion Pharmaceuticals Inc. (U.S.)
- PARI GmbH (Germany)
- Jabil Inc. (U.S.)
- AstraZeneca (U.K.)
- Boehringer Ingelheim International GmbH. (Germany)
- GSK plc. (U.K.)
- Novartis AG (Switzerland)
- Aerogen Pharma (Ireland)
- Briggs Healthcare (U.S.)
- HAAG-STREIT GROUP (Switzerland)
- Janssen Global Services, LLC (U.S.)
- AptarGroup, Inc. (U.S.)
Above are the key players covered in the report, to know about more and exhaustive list of pulmonary drug delivery market companies contact, https://www.databridgemarketresearch.com/es/contact
Research Methodology: Global Pulmonary Drug Delivery Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by dbmr research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, global vs regional and vendor share analysis. Please request analyst call in case of further inquiry.
